Skip to content

The efficacy and safety of dapagliflozin in the treatment of patients with nocturnal hypertension and chronic kidney disease

The efficacy and safety of dapagliflozin in the treatment of patients with nocturnal hypertension and chronic kidney disease

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400094810
Enrollment
Unknown
Registered
2024-12-27
Start date
2025-01-01
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nocturnal hypertension

Interventions

Interventions group:None
Control group:None

Sponsors

The Third Affiliated Hospital of Guangzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Between 18 and 85 years old, regardless of gender; 2. New-onset nocturnal hypertension; 3. Ambulatory blood pressure examination (ABPM) showed the presence of nocturnal hypertension, and the average nocturnal blood pressure was >=120/70mmHg, and there may or may not be daytime hypertension (ambulatory blood pressure daytime mean blood pressure >=135/85mmHg or office blood pressure >=140/90mmH or home self-measured blood pressure >=135/85mmHg); 4. Creatinine clearance eGFR >=25 to =30mg/g; 5. Able to understand and voluntarily sign the informed consent form;

Exclusion criteria

Exclusion criteria: 1.Diabetic; 2.Acute coronary complex or acute cerebrovascular accident occurred in the past 2 months; 3.Patients with severe liver insufficiency; 4.Patients with severe heart failure;

Design outcomes

Primary

MeasureTime frame
Mean baseline changes in blood pressure at night;the change of eGFR;

Secondary

MeasureTime frame
the change of urine protein/creatinine ratio;

Countries

China

Contacts

Public ContactTan Wenpeng

The Third Affiliated Hospital of Guangzhou Medical University

twpeng99@foxmail.com+86 20 81292119

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026